CD274 and non-small cell lung carcinoma: Second, PD-L1 expression status could not be included as a potential confounding or interacting variable in our analyses, because of the availability of nivolumab as a second-line or later therapy and the lack of routine PD-L1 testing in NSCLC patients outside of clinical trials in Japan.